Table 2.

Subgroup analysis of RR of all-grade pneumonitis associated with PD-1 inhibitor

PD-1 inhibitorControlP
GroupNumber of trialsNumber of eventsNumber of patientsNumber of eventsNumber of patientsI2 (%)RR (95% CI)RRInteraction
Cancer type0.55
 NSCLC5521,313591805.98 (2.62–13.63)<0.001
 Melanoma6542,10661,09103.52 (1.69–7.34)<0.001
 Head and neck cancer152361111NA2.35 (0.28–19.89)0.43
Treatment mode0.60
 Combination therapy333466541904.94 (2.05–11.90)<0.001
 Monotherapy10783,189122,01203.74 (2.11–6.63)<0.001
Control type0.29
 Versus ipilimumab3401,275661303.06 (1.35–6.95)0.008
 Versus chemotherapy9712,38061,50705.45 (2.72–10.91)<0.001
Therapeutic agents0.70
 Nivolumab7611,84871,17204.08 (2.07–8.05)<0.001
 Pembrolizumab5501,807594804.78 (2.08–10.97)<0.001
  • Abbreviations: CI, confidence interval; NA, not applicable.